Literature DB >> 24534119

Ductal carcinoma in situ diagnosed at US-guided 14-gauge core-needle biopsy for breast mass: preoperative predictors of invasive breast cancer.

Ah Young Park1, Hye Mi Gweon1, Eun Ju Son1, Miri Yoo1, Jeong-Ah Kim1, Ji Hyun Youk2.   

Abstract

OBJECTIVES: To identify preoperative features that could be used to predict invasive breast cancer in women with a diagnosis of ductal carcinoma in situ (DCIS) at ultrasound (US)-guided 14-gauge core needle biopsy (CNB).
METHODS: A total of 86 DCIS lesions that were diagnosed at US-guided 14-gauge CNB and excised surgically in 84 women were assessed. We retrospectively reviewed the patients' medical records, mammography, US, and MR imaging. We compared underestimation rates of DCIS for the collected clinical and radiologic variables and determined the preoperative predictive factors for upstaging to invasive cancer.
RESULTS: Twenty-seven (31.4%) of 86 DCIS lesions were upgraded to invasive cancer. Preoperative features that showed a significantly higher underestimation of DCIS were palpability or nipple discharge (p=0.040), number of core specimens less than 5 (p=0.011), mammographic maximum lesion size of 25 mm or larger (p=0.022), mammographic mass size of 40 mm or larger (p=0.046), sonographic mass size of 32 mm or larger (p=0.009), lesion size of 30 mm on MR (p=0.004), lower signal intensity (SI) on fat-saturated T2-weighted MR images (FS-T2WI) (p=0.005), heterogeneous or rim enhancement on MR images (p=0.009), and apparent diffusion coefficient (ADC) values lower than 1.04 × 10(-3)mm(2)/s on diffusion-weighted MR imaging (DWI) (p<0.001).
CONCLUSION: Clinical symptom of palpability or nipple discharge, number of core specimen, mammographic maximum lesion or mass size, SI on FS-T2WI, heterogeneous or rim enhancement on MR, and ADC value may be helpful in predicting the upgrade to invasive breast cancer for DCIS diagnosed at US-guided 14-gauge CNB.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Core needle biopsy; Ductal carcinoma in situ; Ultrasound

Mesh:

Year:  2014        PMID: 24534119     DOI: 10.1016/j.ejrad.2014.01.010

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  13 in total

Review 1.  Comparison of the accuracy of US-guided biopsy of breast masses performed with 14-gauge, 16-gauge and 18-gauge automated cutting needle biopsy devices, and review of the literature.

Authors:  Monica L Huang; Kenneth Hess; Rosalind P Candelaria; Mohammad Eghtedari; Beatriz E Adrada; Nour Sneige; Bruno D Fornage
Journal:  Eur Radiol       Date:  2016-11-14       Impact factor: 5.315

Review 2.  Ductal carcinoma in situ of breast: update 2019.

Authors:  Sunil S Badve; Yesim Gökmen-Polar
Journal:  Pathology       Date:  2019-08-28       Impact factor: 5.306

3.  Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer?

Authors:  Michael R Harowicz; Ashirbani Saha; Lars J Grimm; P Kelly Marcom; Jeffrey R Marks; E Shelley Hwang; Maciej A Mazurowski
Journal:  J Magn Reson Imaging       Date:  2017-02-09       Impact factor: 4.813

4.  Diagnostic value of endoscopic appearance during ductoscopy in patients with pathological nipple discharge.

Authors:  Ye Han; Jianyi Li; Sijia Han; Shi Jia; Yang Zhang; Wenhai Zhang
Journal:  BMC Cancer       Date:  2017-05-02       Impact factor: 4.430

Review 5.  Current approach and future perspective for ductal carcinoma in situ of the breast.

Authors:  Chizuko Kanbayashi; Hiroji Iwata
Journal:  Jpn J Clin Oncol       Date:  2017-08-01       Impact factor: 3.019

6.  Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis.

Authors:  Young Duck Shin; Hyung-Min Lee; Young Jin Choi
Journal:  BMC Surg       Date:  2021-03-22       Impact factor: 2.102

7.  Application of deep learning to predict underestimation in ductal carcinoma in situ of the breast with ultrasound.

Authors:  Lang Qian; Zhikun Lv; Kai Zhang; Kun Wang; Qian Zhu; Shichong Zhou; Cai Chang; Jie Tian
Journal:  Ann Transl Med       Date:  2021-02

8.  Sentinel Lymph Node Biopsy Should Be Included with the Initial Surgery for High-Risk Ductal Carcinoma-In-Situ.

Authors:  Ern Yu Tan; Z W Joseph Lo; Chuan Han Ang; Christine Teo; Melanie D W Seah; Juliana J C Chen; Patrick M Y Chan
Journal:  Int Sch Res Notices       Date:  2014-10-29

9.  The usefulness of fluorodeoxyglucose-PET/CT for preoperative evaluation of ductal carcinoma in situ.

Authors:  Sungchul Kim; Seokjae Lee; Sangwon Kim; Seokmo Lee; Hayong Yum
Journal:  Ann Surg Treat Res       Date:  2018-01-30       Impact factor: 1.859

10.  Predictive factors for the presence of invasive components in patients diagnosed with ductal carcinoma in situ based on preoperative biopsy.

Authors:  Kwan Ho Lee; Jeong Woo Han; Eun Young Kim; Ji Sup Yun; Yong Lai Park; Chan Heun Park
Journal:  BMC Cancer       Date:  2019-12-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.